Section Arrow
JBIO.NASDAQ
- Jade Biosciences Inc
Quotes are at least 15-min delayed:2026/07/11 12:49 EDT
Regular Hours
Last
 20.95
-1.53 (-6.81%)
Day High 
23.33 
Prev. Close
22.48 
1-M High
23.49 
Volume 
1.41M 
Bid
18.13
Ask
21.37
Day Low
19.76 
Open
22.775 
1-M Low
15.015 
Market Cap 
1.37B 
Currency 美元 
P/E -- 
%Yield 89.55 
10-SMA 22.02 
20-SMA 19.78 
50-SMA 21.15 
52-W High 28 
52-W Low 6.67 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.63/-2.58
Enterprise Value
1.37B
Balance Sheet
Book Value Per Share
4.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABPmgc Holdings Inc1.12+0.06+5.66%-- 
RXRXRecursion Pharmaceuticals3.56-0.2-5.32%-- 
VYNEVYNE Therapeutics0.6376-0.0344-5.12%-- 
HUMAHumacyte0.6937-0.0066-0.94%-- 
GOSSGossamer Bio0.1697-0.0053-3.03%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.